Breaking News

Redx Pharma Launches R&D Division at AZ Site

May 7, 2013

Will focus on drug resistant bacteria and viral infections

Redx Pharma is opening a new R&D facility at AstraZeneca’s Alderley Park site in Cheshire, UK. The new venture, Redx Anti-Infectives Ltd., will employ a team of 119 scientists to develop drugs combating resistance to antibiotics and new medicines for viral infections. These include the threat of superbugs like MRSA, as well as influenza, hepatitis C and HIV. Redx Anti-Infectives is the third business created by the Redx Pharma group, which includes Redx Oncology and Redx Crop Protection.
Dr. Neil Murray, chief executive of Redx Pharma, said, “The World Health Organization has identified drug resistance, particularly in the area of antibiotics, as one of the most pressing human health concerns globally. The fresh thinking and original approach of Redx Anti-Infectives will help create effective solutions to these critical problems. At Redx, our methods have already uncovered commercial potential that might otherwise have been missed and our approach helps partners to bring new medicines to market faster.”
Clive Morris, AstraZeneca vice president, R&D said, “We are delighted to welcome Redx to Alderley Park, which is an important first step in our ambition to secure a sustainable future for the site. We will continue to seek further opportunities to attract other innovation-driven companies and, wherever possible, build on the existing bioscience expertise and world class facilities available at Alderley Park.”

Related Contract Manufacturing:

  • When Quality Meets Confidence

    When Quality Meets Confidence

    Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS ||November 9, 2016
    A look at global account management for R&D outsourcing

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus